Trial Profile

A Phase 3 Trial of PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis in Adult Patients

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 27 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zopapogene imadenovec (Primary)
Indications Recurrent respiratory papillomatosis
Focus Registrational; Therapeutic Use
Sponsors Precigen Inc

Most Recent Events

06 Aug 2024 Status changed from planning to recruiting.
06 Aug 2024 According to a Precigen Inc media release, PRGN-2012 is on track for a rolling BLA submission under an accelerated approval pathway anticipated in the second half of 2024; patient enrollment initiated in the confirmatory clinical trial.
15 Aug 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com